Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials
Citations Over TimeTop 10% of 2012 papers
Abstract
Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.
Related Papers
- → CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM: NOW IN PAKISTANI PUNJAB(1985)26 cited
- → Chloroquine-Resistant Plasmodium falciparum : Effect of Substrate on Chloroquine and Amodiaquin Accumulation(1974)47 cited
- → Chloroquine resistance of Plasmodium falciparum: a biological advantage?(1995)27 cited
- → RII-RIII chloroquine resistantPlasmodium falciparummalaria from East Africa: studies of thein vivoandin vitroresponse to chloroquine(1983)12 cited
- [Chemoresistance of Plasmodium falciparum in Kinshasha. In vivo tests and chloroquine absorption].(1988)